TreeFrog Therapeutics annopunced that it has received €64 million in a round of funding led by new investor Large Venture Fund, a fund managed by Bpifrance Investissement SAS on September 13, 2021. The transaction also included participation from Bristol-Myers Squibb Company, new investor Leonard Green & Partners, L.P., returning investor Xange Private Equity, S.A. As part of the transaction, Laurent Higueret of Large Venture Fund, a fund managed by Bpifrance Investissement SAS, Peter Zippelius of Leonard Green & Partners, L.P. will join the board of directors of the company, Girish Pendse of Bristol-Myers Squibb Company will join the board as an observer.